Search Results
Jan 06, 2026, 20:00 ET 晶泰科技賦能國內首個「AI + RNA」小分子創新藥獲批臨床，ReviR溪礫科技實現罕見病首創新藥突破
調控路徑在加速罕見病等重要疾病的創新療法突破中的關鍵作用。公司與晶泰科技還有多個在研管線項目合作，有望系統攻克罕見病的全球性治療難題，為更多無藥可醫的患者帶來新的希望。RTX-117 精準靶向 CMT 致病的關鍵生理學機制，通過抑制異常激活的整合應激反應（Integrated Stress Response, ISR）通路，恢復 mRNA 的正常翻譯發揮療效。臨床前數據顯示，RTX-117 不僅在分子層面顯著抑制了 ISR，更在功能層面有效恢復了模型動物的運動能力。這一針對性治療藥物的開發，有望從 CMT 患者的疾病早期階段進行干預，更大程度上減少甚至阻止殘
More news about: 晶泰科技
Jan 06, 2026, 13:27 ET Aperture Therapeutics Announces First-In-Class MMP9 Antisense Oligonucleotide Program for ALS
high-throughput screening and chemical optimization, Aperture has identified multiple potent MMP9-targeting ASOs capable of achieving robust knockdown of MMP9 mRNA and protein while attenuating inflammatory biomarkers implicated in ALS pathology in human iPSC-derived microglia. To enable translational pharmacology
More news about: Aperture Therapeutics
Jan 06, 2026, 08:00 ET Chromatin Bioscience, Mediphage Bioceuticals, and Entos Pharmaceuticals, collaborate on Genetic Medicines Project with support from UKRI Innovate UK and Canadian R&D Funding
vivo cell therapy, and in vivo gene editing. msDNA™ is also a starting material for the production of viral vectors like rAAV and lentiviral vectors, mRNA therapeutics, and DNA vaccines. Mediphage is currently engaged in collaborations with the world's largest pharmaceutical and biotechnology companies
More news about: CHROMATIN BIOSCIENCE LTD
Dec 23, 2025, 20:20 ET Nona Biosciences Expands Integrated Discovery-to-Clinical Capabilities Through Strategic Platform Growth
antibodies as a plug-and-play system, including bispecific antibodies, multi-specific antibodies, CAR-T therapies, antibody-drug conjugates (ADCs), mRNA-based therapeutics, and more.By integrating Harbour Mice®, single-B cell screening technology, NonaCarFx™ (a direct CAR-function-based
More news about: Nona Biosciences
Dec 22, 2025, 22:56 ET GC Biopharma Secures IND Approval for Phase 1 Clinical Trial of COVID-19 mRNA Vaccine in Korea
government's policy initiative to localize mRNA vaccine. GC Biopharma plans to submit Phase 2 IND in the second half of 2026.GC4006A is a COVID-19 vaccine candidate developed using GC Biopharma's proprietary mRNA-LNP (Lipid Nanoparticle) platform. mRNA vaccines are regarded as a critical technology
More news about: GC Biopharma
Dec 21, 2025, 17:43 ET Samsung Biologics Expands U.S. Manufacturing Capabilities with Strategic Acquisition of Human Genome Sciences from GSK
leading capacity, Samsung Biologics continues to advance its diversified portfolio spanning monoclonal antibodies, antibody-drug conjugates (ADCs), mRNA, organoid-based services, and next-generation therapies."This landmark acquisition is a testament to our unwavering commitment to advancing global
More news about: Samsung Biologics
Dec 18, 2025, 21:59 ET Kanazawa University research: a new strategy for immune tolerance
physiological environments. A modular and clinically adaptable immune-tolerance platform Unlike mRNA or nanoparticle-based tolerogenic systems, EVs are naturally derived, highly biocompatible, and capable of presenting multiple functional molecules
More news about: Kanazawa University
Dec 17, 2025, 08:30 ET Xtalks Releases 2025 Webinar Year-in-Review Showcasing Key Life Science Trends
remained a major focus in 2025, with webinars examining cell and gene therapy clinical development and safety, as well as RNA therapeutics, including mRNA characterization, quality control and analytical methods.Webinars also addressed viral vectors and plasmids, along with the manufacturing and
More news about: Xtalks
Dec 17, 2025, 08:01 ET Nona Biosciences and Valink Therapeutics Form Strategic Alliance to Accelerate Novel Biologics Discovery
antibodies as a plug-and-play system, including bispecific antibodies, multi-specific antibodies, CAR-T therapies, antibody-drug conjugates (ADCs), mRNA-based therapeutics, and more.By integrating Harbour Mice®, single-B cell screening technology, NonaCarFx™ (a direct CAR-function-based
More news about: Nona Biosciences
Dec 17, 2025, 08:00 ET The Colossal Foundation Doubles Funding to $100 Million to Prevent Mass Extinctions
endangered wolf species.ENDING THE ELEPHANT EEHV CRISISAccelerating the development of the world's first mRNA vaccine targeting the virus responsible for most juvenile elephant deaths in human care.DECODING THE SECRET LANGUAGE OF
More news about: The Colossal Foundation
Dec 16, 2025, 07:00 ET Replicate Bioscience Appoints Kathy Fernando, Ph.D., as Chief Business Officer
existing mRNA approaches, with potential improvements in bioactivity, induction of more potent immune responses, and improved therapeutic index. RBI-4000, the company's clinical-stage srRNA rabies vaccine, has demonstrated protective levels of immunity at doses lower than any other reported mRNA or srRNA
More news about: Replicate Bioscience
Dec 16, 2025, 05:59 ET Breakthrough Progress: METiS TechBio Publishes Consecutive Research Findings in Nature Communications and the Journal for ImmunoTherapy of Cancer
lipid nanoparticle (LNP) delivery systems with programmable mRNA engineering, METiS has developed a new generation of immunotherapy strategies capable of efficiently activating antitumor immunity in specific organs in vivo.MTS-105 is a first-in-class mRNA-encoded T cell engager (TCE) therapy candidate
More news about: METiS TechBio
Dec 15, 2025, 08:00 ET Diakonos Oncology to Present Corporate Overview and Participate in Panel at 2026 Biotech Showcase
patient-derived double-loaded dendritic cell therapy that uniquely combines tumor lysate and amplified tumor-derived mRNA. The immunotherapy is made with a patient's dendritic cells combined with mRNA and proteins prepared from freshly obtained patient tumor specimens.The unique double-loading approach,
More news about: Diakonos Oncology
Dec 12, 2025, 10:47 ET Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance
Inc. (NASDAQ: ONCY), Immuneering Corporation (NASDAQ: IMRX), Tango Therapeutics, Inc. (NASDAQ: TNGX), Moderna, Inc. (NASDAQ: MRNA), and Royalty Pharma plc (NASDAQ: RPRX) as companies advancing breakthrough approaches in one of oncology's most challenging indications.
More news about: USA News Group
Dec 10, 2025, 18:30 ET Samsung Biologics recognized as a global leader in water security
cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics.By implementing the ExellenS™ framework across its manufacturing network with standardized designs, unified processes, and advanced
More news about: Samsung Biologics
Dec 10, 2025, 17:31 ET Pancreatic Cancer Market Set to Expand During the Forecast Period (2025-2034) as Precision Medicine and Immunotherapy Transform Treatment Landscape | DelveInsight
treated metastatic pancreatic ductal adenocarcinoma (PDAC), with results anticipated in 2026.BioNTech/Genentech's BNT122, an individualized mRNA-based cancer vaccine developed in collaboration with Genentech, aims to generate neoantigen-specific immune responses. It is being tested in a Phase
More news about: DelveInsight Business Research, LLP
Dec 10, 2025, 08:00 ET Diakonos Oncology Awarded Multi-Million-Dollar Research Grant by the Cancer Prevention and Research Institute of Texas to Advance DOC1021 in Refractory Melanoma
patient-derived double-loaded dendritic cell therapy that uniquely combines tumor lysate and amplified tumor-derived mRNA. The immunotherapy is made with a patient's dendritic cells combined with mRNA and proteins prepared from freshly obtained patient tumor specimens. The unique double-loading approach,
More news about: Diakonos Oncology
Dec 09, 2025, 11:57 ET Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
Equity Insider News Commentary – Traditional pharmaceutical strategies are giving ground as breakthrough approvals for gene therapies and mRNA platforms target previously untreatable rare diseases with precision interventions[1]. Healthcare systems integrating AI diagnostic tools
More news about: Equity Insider
Dec 09, 2025, 10:20 ET Immunostimulant Market to Reach $288.82 billion, Globally, by 2034 at 9.9% CAGR: Allied Market Research
immunostimulant use globally.The market presents substantial opportunities as well. First, advancements in next-generation vaccines including mRNA-based, vector-based, and peptide vaccines are revolutionizing preventive medicine.These platforms offer rapid development cycles, strong efficacy
More news about: Allied Market Research
Dec 09, 2025, 08:00 ET CREATE Medicines Doses First Patient in Frontline HCC Trial Evaluating MT-303, an In Vivo CAR Therapy, in Combination with Standard-of-Care Immunotherapy
trial evaluating MT-303. The study is assessing MT-303, an investigational in vivo GPC3-targeted CAR therapy delivered by the company's proprietary mRNA-LNP platform, in combination with atezolizumab and bevacizumab, the current global standard-of-care regimen for frontline HCC.
More news about: CREATE Medicines, Inc.
Dec 09, 2025, 08:00 ET Vincere Cancer Center Begins Recruitment for Clinical Studies of Pioneering Breast Cancer Screen for Women at High Risk
US cancer center partners with Syantra Inc. for further testing of Onco-ID Breast, a whole blood mRNA test for hyper-early cancer detectionCALGARY, AB, Dec. 9, 2025 /PRNewswire/ - Syantra, Inc., a biotechnology company
More news about: Syantra Inc.
Dec 08, 2025, 05:35 ET Exosomes Market Led by North America with 53% Revenue Share and Global Market Size Set to Surpass USD 2B by 2030, Says Mordor Intelligence
Spectrometry By Biomolecule Type Non-coding RNA (miRNA, lncRNA)Proteins & PeptidesLipidsmRNADNA FragmentsBy Application Diagnostics Cancer Neuro-degenerative
More news about: Mordor Intelligence Private Limited
Dec 07, 2025, 08:00 ET Orna Therapeutics Presents New Data Supporting its in vivo CAR Programs for Autoimmune Diseases and Oncology at the 67th American Society of Hematology Annual Meeting
therapeutics to unlock the potential of RNA medicine to treat diseases anywhere in the body. Orna's oRNA transcripts have advantages over traditional mRNA approaches, including simplified production, improved formulation into lipid nanoparticles, and superior protein expression. Its industry-leading LNP-based
More news about: Orna Therapeutics
Dec 06, 2025, 09:45 ET Vivacta Bio Announces Promising First-in-Human Results for GT801, an In Vivo CAR-T Therapy, in Non-Hodgkin's Lymphoma at the 2025 ASH Annual Meeting
for oncology and autoimmune diseases, today announced encouraging initial data from an investigator-initiated, first-in-human study of GT801, a T-LNP/mRNA–based in vivo CAR-T candidate targeting CD19. The results were presented in an oral session by Dr. Pin Wang, Chief Scientific Officer of Grit Biotherapeutics,
More news about: Vivacta Biotechnology Co., Ltd.
Dec 04, 2025, 15:17 ET AlidaBio Introduces the EpiPlex™ Duo-Mod™ Service for Concurrent m6A and Inosine Mapping with Integrated RNA Expression Profiling
AlidaBio's EpiPlex assay, and it appears to excel at both."The EpiPlex Duo-Mod Service supports m6A and inosine mapping from as little as 20 ng mRNA or 250 ng total RNA and accepts human, mouse, and rat samples, with additional species available upon request. AlidaBio performs the complete workflow,
More news about: Alida Biosciences